Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599194 · ClinicalTrials.gov registry record · Phase 2
18F-FSPG PET/CT for Cancer Patients on Therapy
A Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02599194 is a Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative that has completed, run by Andrei Iagaru. The registered enrollment target is 7 participants, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02599194, a Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.
Conditions Studied
Interventions
- DRUG 18F-FDG
- DRUG 18F-FSPG
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02599194
The ClinicalTrials.gov registry entry for NCT02599194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-FDG is the first listed.
NCT02599194 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02599194 about?
NCT02599194 is a clinical study titled "18F-FSPG PET/CT for Cancer Patients on Therapy". The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.
What is the current status of trial NCT02599194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-07. Estimated completion is 2016-12-14.
What conditions does trial NCT02599194 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, HER2/Neu Negative, Estrogen Receptor Negative, Progesterone Receptor Negative, Stage IIIB Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT02599194?
The interventions under investigation include: 18F-FDG (DRUG), 18F-FSPG (DRUG).
Who is sponsoring clinical trial NCT02599194?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02599194 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.